Drug intelligence / Profile preview

CD70-encoding RNA nanoparticle

Development stage
Unknown
Modality
mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intratumoral, Intranodal, Intravenous
01

Overview

CD70-encoding RNA nanoparticle is a therapeutic modality consisting of messenger RNA (mRNA) that encodes the Cluster of Differentiation 70 (CD70) protein, encapsulated within a nanoparticle delivery system, typically lipid nanoparticles (LNPs). CD70 is the biological ligand for CD27, a co-stimulatory receptor expressed on T cells and NK cells. When the mRNA is delivered to and translated by target cells (such as dendritic cells or cells within the tumor microenvironment), the resulting CD70 protein is expressed on the cell surface. This expression provides a potent co-stimulatory signal (Signal 2) for T-cell activation, enhancing the magnitude and duration of the anti-tumor immune response. This approach is often used as an adjuvant strategy in cancer vaccines or as part of a multi-mRNA cocktail (e.g., TriMix) to improve the maturation and stimulatory capacity of antigen-presenting cells.

Other names
CD70 mRNA nanoparticleCD-70 mRNA nanoparticleCD 70 mRNA nanoparticlemRNA-encoded CD70CD70-encoding mRNA nanoparticleCD-70-encoding mRNA nanoparticleCD 70-encoding mRNA nanoparticle
02

Targets

Beyond the preview

Go deeper on CD70-encoding RNA nanoparticle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD70-encoding RNA nanoparticle.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call